Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors
- PMID: 2848122
Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors
Abstract
The shape of the time-course of cyclic AMP formation by intact human platelets in response to the stable prostaglandin I2 analogue iloprost varied with the concentration of the prostaglandin. At low concentrations of iloprost, the time-course showed a rise to a plateau with little subsequent decrease in cyclic AMP level. At high concentrations of iloprost, the initial rate of cyclic AMP formation was more rapid than at low concentrations, but the curves showed a marked time-dependent fall in cyclic AMP level to values below those observed at lower prostaglandin concentration. By contrast, PGE1 gave a rise and marked fall in cyclic AMP level at all concentrations of the prostaglandin and the curves did not cross. The time- and concentration-dependent fall in cyclic AMP level in response to iloprost was still apparent in the presence of phosphodiesterase inhibitors, indicating that inhibition of adenylate cyclase, rather than activation of cyclic AMP phosphodiesterases, was responsible for the fall in cyclic AMP level. Activators of protein kinase C, which phosphorylates platelet Ni and impairs its function, abolished the time-dependent fall in cyclic AMP level, indicating that Ni may be involved in prostaglandin-induced inhibition of adenylate cyclase. Time-courses were analyzed using an equation derived by Barber et al. (Adv. Cyc. Nuc. Res. 9, 507-516 (1978)) to yield rate constants for activation and inhibition of adenylate cyclase. Because of the difference in prostaglandin dependence of the activation and inhibition rate constants we propose that activation of adenylate cyclase in platelets is mediated by a rapid-acting stimulatory receptor, while time-dependent inhibition (desensitization) is mediated through a separate, slow-acting inhibitory receptor. The stimulatory receptor has an affinity for prostaglandin greater than the putative inhibitory receptor in the case of iloprost (as well as PGI2 and PGD2), and a lower affinity than the inhibitory receptor in the case of PGE1 (and PGE2). Prostaglandin-induced inhibition may be mediated through Ni.
Similar articles
-
Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities.Mol Pharmacol. 1989 Dec;36(6):866-73. Mol Pharmacol. 1989. PMID: 2481225
-
Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets.Mol Pharmacol. 1990 Jul;38(1):46-53. Mol Pharmacol. 1990. PMID: 1695318
-
Kinetic evidence indicating separate stimulatory and inhibitory prostaglandin receptors on platelet membranes.J Cyclic Nucleotide Protein Phosphor Res. 1986;11(4):291-300. J Cyclic Nucleotide Protein Phosphor Res. 1986. PMID: 2432105
-
Interactions among prostaglandin receptors.Receptor. 1994 Spring;4(1):31-42. Receptor. 1994. PMID: 8038705 Review.
-
Enzymatic regulation of mast cell activation and secretion by adenylate cyclase and cyclic AMP-dependent protein kinases.Fed Proc. 1982 Jan;41(1):22-9. Fed Proc. 1982. PMID: 6173264 Review.
Cited by
-
Comparison of the effects of prostaglandins E2 and I2 on testicular nociceptor activities studied in vitro.Naunyn Schmiedebergs Arch Pharmacol. 1991 Sep;344(3):368-76. doi: 10.1007/BF00183013. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1961261
-
Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.Br J Pharmacol. 1993 Feb;108(2):363-9. doi: 10.1111/j.1476-5381.1993.tb12810.x. Br J Pharmacol. 1993. PMID: 8448586 Free PMC article.
-
Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation.J Clin Invest. 2001 Mar;107(5):603-10. doi: 10.1172/JCI10881. J Clin Invest. 2001. PMID: 11238561 Free PMC article.
-
Who is the real 12-HETrE?Prostaglandins Other Lipid Mediat. 2017 Sep;132:25-30. doi: 10.1016/j.prostaglandins.2017.02.005. Epub 2017 Mar 1. Prostaglandins Other Lipid Mediat. 2017. PMID: 28259546 Free PMC article. Review.
-
Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.Thromb Res. 2015 Sep;136(3):493-503. doi: 10.1016/j.thromres.2015.05.027. Epub 2015 May 28. Thromb Res. 2015. PMID: 26077962 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous